NCT01618279|Completed
Tryptase and Coronary Heart Disease
Evaluation of Tryptase as a Biomarker of Coronary Heart Disease
Loading search results
Evaluation of Tryptase as a Biomarker of Coronary Heart Disease
Sponsor study identifier
observational
350
1 country
1
Study Start
January 2013
Actual (reported)Primary Completion
December 2021
Actual (reported)Study Completion
January 2022
Actual (reported)The main aim of this study will evaluate differences in serum levels of tryptase in study population. Will be selected a number of 350 patients hospitalized for coronary heart disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 11, 2012
Actual (reported)June 13, 2012
Actual (reported)January 2013
Actual (reported)December 2021
Actual (reported)January 2022
Actual (reported)serum level of tryptase as a biomarker in coronary
dose level of serum tryptase already performed by venipuncture from diagnostic practices
6 months
Tryptase and major cardiovascular events
6 months
Tryptase and major cardiovascular events
6 months
Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
Italian subjects in the acute phase of disease and follow up. The work will be on 4 patient populations: 1. sindrome coronary acute ST elevation on electrocardiogram 2. sindrome ACS without ST elevation on electrocardiogram (acute myocardial infarction with ST-segment depression on electrocardiogram and unstable angina) 3. malattia critical coronary artery stenosis \<50% 4. aneurismi aorta.
AO Osepdale Niguarda Ca' Granda
Milan, 20162, Italy
Morici N, Farioli L, Losappio LM, Colombo G, Nichelatti M, Preziosi D, Micarelli G, Oliva F, Giannattasio C, Klugmann S, Pastorello EA. Mast cells and acute coronary syndromes: relationship between serum tryptase, clinical outcome and severity of coronary artery disease. Open Heart. 2016 Sep 27;3(2):e000472. doi: 10.1136/openhrt-2016-000472. eCollection 2016.
Pastorello EA, Morici N, Farioli L, Di Biase M, Losappio LM, Nichelatti M, Lupica L, Schroeder JW, Stafylaraki C, Klugmann S. Serum tryptase: a new biomarker in patients with acute coronary syndrome? Int Arch Allergy Immunol. 2014;164(2):97-105. doi: 10.1159/000360164. Epub 2014 Jun 14.
Venous blood
Elide Anna Pastorello, MD, Professor
Azienda Ospedaliera Ospedale Niguarda Ca' Granda
350 participants (actual enrollment reported by the registry).
First Submitted
June 11, 2012
First Posted
June 13, 2012
Study Start
January 2013
Actual (reported)ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
Contact the study team to confirm eligibility.
Pastorello EA, Farioli L, Losappio LM, Morici N, Di Biase M, Nichelatti M, Schroeder JW, Balossi L, Klugmann S. Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years. Clin Mol Allergy. 2015 Jun 2;13(1):14. doi: 10.1186/s12948-015-0013-0. eCollection 2015.
Losappio LM, Mirone C, Chevallard M, Farioli L, De Luca F, Pastorello EA. Tryptase as a marker of severity of aortic valve stenosis. Clin Mol Allergy. 2018 Aug 7;16:17. doi: 10.1186/s12948-018-0095-6. eCollection 2018.
Primary Completion
December 2021
Actual (reported)Study Completion
January 2022
Actual (reported)Last Updated
January 25, 2022
Record last verified: 2022-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: